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Combination antiretroviral therapy (cART) has tremendously 
reduced HIV-associated morbidity, mortality and mother-to-child 
transmission (MTCT).[1] The Option B+ (lifelong cART for all 
HIV-infected pregnant and breastfeeding women) introduced by 
the World Health Organization proved to be effective, resulting 
in a reduction of MTCT from 33% (before ART) to <2% in sub-
Saharan Africa.[2] Despite the massive success in reduction of 
MTCT, HIV-exposed uninfected (HEU) children experience delayed 
developmental milestones, disabilities and more frequent morbidities 
than their HIV-unexposed counterparts.[3,4] Developmental and 
health problems in some HEU infants occur despite maternal cART 
during pregnancy. Differential HIV outcomes have previously been 
associated with interindividual variation in response to cART.[5] 
The differential outcomes of cART during pregnancy are critical 
in the care of HEU infants who have to endure effects of in utero 
and postpartum exposure to antiretroviral drugs.[6] Furthermore, 
the increasing number of HIV-infected adolescents who grow into 
adulthood with a strong will to procreate, further emphasises the need 
to understand the factors associated with different HIV treatment 
outcomes in pregnancy, which also determine infant outcomes.[7] Of 
the utmost importance during pregnancy are antenatal diseases that 
may result in adverse outcomes if transmitted to the developing fetus 
or neonate. Antenatal infections (such as cytomegalovirus (CMV), 
toxoplasmosis, syphilis and rubella) are more prevalent among HIV-
infected than HIV-uninfected women.[8,9] 
CMV is a latent beta herpesvirus that is often reactivated in immune-
compromised populations such as HIV patients and pregnant 
women. When reactivation of CMV occurs during pregnancy, the 
virus can be transmitted to the fetus and/or neonate, resulting in 
congenital CMV (cCMV) infection.[10] Effects of cCMV may be 
potentially fatal and include paediatric pneumonia, neurocognitive 
developmental delay and sensorineural hearing loss, for which 
CMV is the leading non-genetic cause.[11,12] In a review by Filteau 
and Rowland-Jones,[13] vertical transmission of CMV in utero or in 
early infancy was hypothesised to be responsible for the health and 
developmental deficits in HIV-exposed children. cCMV is sustained 
by antenatal CMV infection or reactivation; hence, controlling 
maternal CMV infection is key in the prevention of cCMV. cART 
is protective against the emergence of opportunistic infections;[14] 
therefore, the occurrence of CMV in some but not all HIV-infected 
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Background. Effective combination antiretroviral therapy (cART) has tremendously reduced HIV-associated morbidity, mortality and 
mother-to-child transmission. However, the benefits of cART are threatened by comorbidities, adverse drug reactions and virus resistance 
to existing treatment regimens. One of the most occurring comorbidities is cytomegalovirus (CMV) infection. 
Objectives. To investigate the effects of cART on the occurrence of CMV infection among pregnant women. 
Methods. Using a cross-sectional study design, 175 HIV-infected pregnant women were recruited, and data were obtained from their 
clinical records. Blood samples were collected for host DNA, CMV DNA and plasma efavirenz (EFV) measurement. CMV DNA was 
measured using real-time polymerase chain reaction (PCR). CYP2B6 c.516G>T and CYP2B6 c.983T>C single nucleotide polymorphisms 
were characterised using PCR/restriction fragment length polymorphism and TaqMan assays, respectively. Plasma EFV concentrations were 
determined using high-performance liquid chromatography.
Results. There was an inverse association between plasma EFV concentration and CMV DNA. Participants with lower plasma EFV 
concentrations were significantly (p<0.001) more likely to be CMV DNA positive than those with higher plasma concentrations. This result 
is also supported by the observation that carriers of CYP2B6 poor-metaboliser genotypes (CYP2B6 c.516T/T and CYP2B6 c.983T/C) were 
less likely to be positive for CMV DNA. Furthermore, poor metabolism as denoted by CYP2B6 c.516T/T and CYP2B6 c.983T/C genotypes 
was significantly associated with lower CMV viral load. 
Conclusions. HIV treatment disrupts the balance between host and co-infecting microbes. Reduced or subtherapeutic levels of 
antiretroviral drugs, which could be exacerbated by genetic polymorphisms in drug metabolism genes and non-adherence, predispose 
infected individuals to an increased risk of CMV infection in pregnancy. 
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pregnant women could suggest differences in protectivity of cART 
against co-infections. 
In resource-limited settings, the choice of cART Option B+ is 
a combination of two nucleoside reverse transcriptase inhibitors 
(NRTIs) (tenofovir (TDF) and lamivudine (3TC)/emtricitabine 
(FTC)) and one non-nucleoside reverse transcriptase inhibitor 
(NNRTI) (efavirenz (EFV)). The use of EFV-based regimens 
among pregnant women has been recommended, as EFV has fewer 
drug interactions and fewer adverse drug reactions than other 
antiretroviral drugs.[15] Therefore, EFV is the NNRTI of choice for 
first-line treatment of HIV infection in pregnancy. 
EFV is administered as a once-daily oral dose of 600 mg and is mainly 
metabolised by cytochrome P450 2B6 (CYP2B6), a hepatic enzyme 
encoded by the CYP2B6 gene.[16] However, genetic polymorphisms 
in CYP2B6 affect the pharmacokinetics of EFV, leading to variability 
in EFV steady-state concentrations.[17,18] Participants in this study 
were administered EFV-based cART regimens; therefore, EFV will 
be used as a proxy for cART in this report on susceptibility to 
CMV infection during pregnancy. The therapeutic effect of a drug 
is influenced by its rate of metabolism and excretion, which can 
be approximated by the plasma concentration of the drug.[4,18] Two 
single nucleotide polymorphisms CYP2B6 c.516G>T (rs3745274) 
and CYP2B6 c.983T>C (rs28399499) in the CYP2B6 affect EFV 
metabolism.[19] Moreover, we also investigated associations between 
plasma EFV concentration and CMV infection. CYP2B6 genotypes 




In this cross-sectional study, HIV-infected pregnant women were 
enrolled through the University of Zimbabwe College of Health 
Sciences birth cohort study. These women were receiving TDF, 3TC 
and EFV 600 mg, prescribed as part of their routine clinical care and 
for prevention of MTCT (PMTCT). Inclusion criteria were: gesta-
tional age ≥20 weeks, maternal age >18 years, HIV infected on cART, 
and presenting for routine antenatal care at any one of three council 
polyclinics in the high-density suburbs of Kuwadzana, Dzivarasekwa 
and Glen View in Harare, Zimbabwe. The HIV status of the partici-
pants was obtained from clinic records, but additional confirmatory 
HIV testing was done at the time of sample collection.[20] CMV DNA 
status and CMV viral loads were determined by real-time polymerase 
chain reaction (RT-PCR) using a RealStar CMV PCR Kit 1.0 (Altona 
Diagnostics, Germany), according to the manufacturer’s instructions. 
Results for CMV status and CMV viral loads were available from the 
main cohort records.
Ethical approval
This study received ethical clearance from the Medical Research 
Council of Zimbabwe (ref. no. MRCZ/A/2177) and the University 
of Cape Town Institutional Review Board (ref. no. HREC628/2017). 
The study was carried out in accordance with the guidelines of the 
Helsinki Declaration of 2008 ethics clearance. Written informed 
consent was obtained from each participant prior to data and 
sample collection. A questionnaire was used to collect participant 
demographical information, and clinical parameters were obtained 
from the participants’ medical records. A 5 mL ethylenediaminetetra-
acetic acid (EDTA) anticoagulated blood sample was collected from 
each participant at least 8 hours after administering a dose. Plasma 
was isolated from 3 mL of the whole blood sample (centrifugation at 
3 000 g for 10 minutes) within 12 hours of venepuncture and stored 
at −80°C for EFV concentration measurement, while the remainder 
of the sample was used for DNA isolation.
Determination of plasma efavirenz concentration and 
CYP2B6 genotypes
Plasma EFV concentrations were quantified at the University of 
Zimbabwe-International Pharmacology Specialty Laboratory 
(UZ-IPSL) using high-performance liquid chromatography (HPLC). 
A photodiode array detector scanning at 247 nm wavelength was 
used for quantification of EFV. The assay had a lower limit of 
quantitation of 500 ng/mL with an interday imprecision coefﬁcient 
of variance (CV) ranging from 1.0% to 5.6%, as determined using 
the quality-control samples. The method used for EFV quantification 
was validated and approved by Clinical Pharmacology Quality 
Assurance (CPQA), an external quality assurance body. UZ-IPSL 
participates in the CPQA annual proficiency testing.
One of the factors that could affect plasma EFV is genetic 
variation in the CYP2B6 gene. The CYP2B6 gene encodes for 
the enzyme principally involved in the metabolism of EFV, and 
two polymorphisms (CYP2B6 c.516G>T and CYP2B6 c.983T>C) 
have been shown to affect steady-state EFV exposure. Therefore, 
the contribution of CYP2B6 genetic variation in EFV therapeutic 
effects and risk of CMV acquisition needed to be determined. 
Host genomic DNA was extracted from whole blood using the 
Quick-DNA Miniprep Plus Kit (Zymo Research, USA) according to 
manufacturer’s instructions. We genotyped for  CYP2B6 c.516G>T 
using restriction fragment length polymorphism.[21] CYP2B6 c.983T>C 
was genotyped using real-time allelic discrimination PCR on the Bio-
Rad CFX96 (Bio-Rad Laboratories, USA). TaqMan SNP Genotyping 
Assay and TaqMan Universal Master Mix were used to genotype 
CYP2B6 c.983T>C (rs28399499; assay ID C_4362691_10). All 
components were purchased from Thermo Fisher Scientific, USA, 
and genotyping was done according to manufacturer’s instructions. 
Genotyping of single nucleotide polymorphisms (SNPs) was done 
at the Division of Human Genetics, Faculty of Health Sciences, 
University of Cape Town, South Africa.
Statistical analysis 
Data were compiled and managed in Research Electronic Data 
Capture (REDCap).[22] Statistical analyses were performed using 
Stata SE, version 15 (StataCorp, USA). Numerical variables were 
described as either median with interquartile range (IQR) for 
non-parametric variables or mean with standard deviation (SD) 
for parametric variables. Categorical variables were described as 
frequencies. Demographic and clinical characteristics were compared 
between CMV-infected and CMV-uninfected participants using t-tests 
for parametric data, Mann-Whitney tests for non-parametric data and 
χ2 tests for categorical data. Plasma EFV concentrations and HIV viral 
load were compared among participants based on CMV DNA status 
using the Mann-Whitney test. The χ2 test was used to determine 
the association between CMV infection status and EFV therapeutic 
groups. The relationship between CMV DNA load and HIV viral 
load was determined using Spearman’s correlation coefficient test. 
Multivariate logistic regression was then performed to control for 
confounders such as maternal age, gestational age, gravidity, body 
mass index (BMI) and CD4+ count. Plasma EFV concentrations were 
compared among CYP2B6 c.516G>T genotypes using the Kruskal-
Wallis rank sum test and between CYP2B6 c.983T>C genotypes using 
the Mann-Whitney test. The correlation between EFV concentration 
and plasma HIV viral load was determined using Spearman’s 
correlation coefficient. Statistical significance was set at p<0.05.
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Results 
Demographic and clinical characteristics of participants
The demographic characteristics of the study participants are 
presented in Table 1. A total of 175 HIV-infected pregnant women who 
were receiving EFV-containing first-line cART were enrolled into the 
study. EFV concentration values were present in all 175 participants. 
CYP2B6 c.516G>T and CYP2B6 c.983T>C SNP genotyping was also 
successfully done. All participants were in the reproductive age group 
(mean (range) 30 (18 - 44) years) and had been receiving EFV-based 
cART from a minimum of 2 months to a maximum of 140 months. 
The mean (SD) CD4+ cell count was 358 (215) µL, while the median 
(25th - 75th percentile) HIV viral load was 97 (10 - 400) copies/mL. 
Results for CMV DNA status of the participants were available from 
the main study records. Of the 175 study participants, 27 (15.4%) 
had CMV DNA detected and quantified in their plasma. The median 
(range) CMV viral load was 366 (108 - 103 355) copies/mL.
Plasma efavirenz concentration distribution
Plasma EFV concentrations were determined for all 175 participants 
from blood drawn at least 8 hours post dose. Participants self-
reported good adherence (did not miss >1 dose since pregnancy). 
The median (25th - 75th percentile) plasma EFV concentration 
for this cohort of pregnant women was 1 850 (990 - 3 963) ng/mL. 
The plasma EFV concentrations ranged from 250 to 15 931 ng/mL, 
exhibiting interindividual variability among patients despite them 
receiving the same 600 mg daily EFV dose. Based on previously 
described therapeutic ranges,[23] plasma EFV concentrations were 
assigned to three groups: subtherapeutic (<1 000 ng/mL), therapeutic 
(1 000 - 4 000 ng/mL) and supratherapeutic (>4 000 ng/mL) range. 
The distribution of plasma EFV concentration among participants 
according to categories was as follows: 44 (25%) in the subtherapeutic 
range, 90 (51%) in the therapeutic range, and 41 (24%) in the 
supratherapeutic range.
Association between CMV DNA positivity and plasma 
efavirenz concentration 
CMV DNA-positive women may be at risk of transmitting CMV to 
their offspring with potentially debilitating effects – with a greater 
risk of transmission in HIV-infected women. We investigated the 
possible role of plasma EFV concentration and consequently HIV 
disease progression (determined by HIV viral load) on maternal 
plasma CMV DNA status in participants who were HIV-CMV 
co-infected. CMV DNA was detected in the plasma of 27 participants 
(15.4%). 
The association between plasma EFV concentration and plasma 
CMV DNA positivity was determined using the Mann-Whitney test. 
Fig. 1 shows the effects of plasma EFV concentration on CMV DNA 
positivity. Reduced plasma EFV concentration (median (25th - 75th 
percentile) 847 (250 - 3 307) ng/mL) was significantly associated with 
CMV DNA positivity (p<0.001) compared with the higher plasma 
EFV concentration (median (25th - 75th percentile) 2 024 (250 - 
14 039) ng/mL). Using the χ2 test, we found a significant decrease 
(p<0.001) in the proportion of CMV positivity and plasma EFV 
concentration groups. The distribution of CMV DNA positivity 
in the three plasma EFV concentration groups was as follows: 
subtherapeutic (76%), therapeutic (16%) and supratherapeutic (8%). 
Furthermore, using Spearman’s correlation test, plasma concen-
trations inversely correlated with CMV viral load. Log plasma EFV 
concentration significantly decreased with increasing CMV viral load 
(r=−0.4; p=0.03).
Using the Mann-Whitney test, CMV DNA positivity was 
significantly associated (p<0.001) with higher HIV viral load (median 
Table 1. Participants’ demographic and clinical characteristics
Characteristic Participants, N=175 CMV negative, n=148 CMV positive, n=27 p-value
Demographics
Mean (SD) maternal age, years 30 (6) 30 (6) 29 (6) 0.182†
Mean (SD) gestational age, weeks 32 (5) 32 (5) 32 (4) 0.945† 
Mean (SD) gravidity 3 (1) 3 (1) 3 (2) 0.285† 
Mean (SD) parity 1.7 (1) 2 (1) 1 (1) 0.052†
Median (25th - 75th) BMI, kg/m2 29 (23 - 28) 26 (24 - 28) 25 (23 - 28) 0.232‡
Median time on cART (25th - 75th), months 18 (2 - 55) 18 (2 - 54) 16 (2 - 75) 0.862‡











Laboratory and clinical parameters
Median CD4+ count (25th - 75th), cells/μL 377 (198 - 511) 405 (228 - 514) 209 (50 - 405) 0.012*‡
Median VL (25th - 75th), copies/mL 97 (10 - 1 400) 49 (10 - 686) 3 033 (76 - 87 604) <0.001*‡ 
CMV = cytomegalovirus; SD = standard deviation; 25th - 75th = interquartile range; BMI = body mass index; cART = combination antiretroviral therapy; VL = HIV viral load.  
*Statistically significant.
†t-test. 
‡Mann-Whitney rank sum test.
§χ2 test.
p<0.001









































LFig. 1. Comparison of plasma EFV concentration between CMV-infected 
and CMV-uninfected participants. Data are presented with median and 
interquartile ranges. (EFV = efavirenz; CMV = cytomegalovirus.)
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(25th - 75th percentile) 3 033 (76 - 87 604) copies/mL) compared with 
CMV-uninfected women (median (25th - 75th percentile) 49 (10 - 
686) copies/mL) (Fig. 2). A stepwise multivariate logistic regression 
analysis was employed to account for the possible confounding 
factors, including maternal age, gestational age, BMI, gravidity, HIV 
viral load, CD4+ T-lymphocyte and plasma EFV concentration on 
plasma CMV DNA status (Table 2). Plasma EFV concentration and 
HIV viral load were the significant determinants of plasma CMV 
DNA positivity in the final multivariate model.
Association of efavirenz with drug response genotypes
The possible role of genetic variation in CYP2B6 regarding the 
variability in plasma EFV concentration was determined by 
genotyping two polymorphisms, CYP2B6 c.516G>T and CYP2B6 
c.983C>T. In agreement with previous findings, plasma EFV 
concentrations were correlated with CYP2B6 genotypes. CYP2B6 
poor-metaboliser genotypes had significantly higher plasma EFV 
concentrations compared with CYP2B6 extensive metabolisers. 
Comparisons across the genotype groups for both CYP2B6 c.516G>T 
and CYP2B6 c.983C>T were significantly different (p<0.001). For 
example, median plasma EFV concentrations for CYP2B6 c.516G/G, 
CYP2B6 c.516G/T, CYP2B6 c.516T/T, CYP2B6 c.983T/T and 
CYP2B6 c.983T/C were as follows: 1 027 ng/mL, 2 108 ng/mL, 
7 074 ng/mL, 1 695 ng/mL and 7 228 ng/mL, respectively. 
Discussion
There is an increasing number of people living with HIV, who receive 
chronic cART. The biggest challenge in patient outcomes is the effect 
of long-term cART on susceptibility to and pathological dynamics 
of HIV co-infections.[24] Even in the presence of cART, which 
has dramatically reduced the vertical transmission of HIV, cCMV 
remains a public health concern owing to late and underdiagnosis.[25] 
In this study, we report a significant association between detection of 
plasma CMV DNA and subtherapeutic plasma EFV concentrations 
in pregnant women administered an EFV-based first-line cART 
regimen. The study also confirms the known significant association 
between plasma EFV concentrations and genetic variation in CYP2B6, 
as previously reported by Swart et al.[19] and Lamorde et al.[26]
All participants were enrolled >8 hours after the EFV dose 
to ensure a time-point beyond the EFV absorption phase.[27] 
Furthermore, all enrolled participants had been on an EFV-based 
regimen for >4 weeks, ensuring steady-state phase. However, drug 
adherence was reported by participants, which may have introduced 
bias. Assessment of adherence to ART is a major conundrum in the 
care of HIV patients due to potential patient misrepresentation. More 
effective methods of adherence assessment, such as the medication 
event monitoring systems (MEMS) cap,[28] remain largely inaccessible 
owing to cost. The wide range of the plasma EFV concentration (250 - 
15 931 ng/mL) observed is indicative of the interindividual variability 
in exposure to therapy. Of note, 25% and 24% of participants were 
in the subtherapeutic and supratherapeutic groups, respectively. 
Regardless of patients receiving the same drug dosage, a great deal 
of variability in pharmacokinetics and treatment outcomes has also 
been documented for various drugs such as warfarin, digoxin and 
tacrolimus. 
Several environmental, demographic and clinical factors have 
been implicated in the interindividual variability in response to 
therapy.[29-31] However, in this study, no association between plasma 
EFV concentrations and demographic markers, such as maternal 
p<0.001










































Fig. 2. Comparison of HIV viral load between CMV-infected and CMV-
uninfected participants. Data are presented with median and interquartile 
ranges. (CMV = cytomegalovirus.)
Table 2. Stepwise logistic regression of clinical and demographic variables associated with cytomegalovirus DNA status
Variables Odds ratio Standard error p-value 95% CI
Gestational age 1.0 0.56 0.843 0.93 - 1.15
Gravidity 0.8 0.22 0.496 0.48 - 1.37
Maternal age 1.0 0.06 0.767 0.91 - 1.14
BMI 0.9 0.06 0.256 0.83 - 1.05
CD4+ count† 0.9 0.03 0.092 0.99 - 1.00
HIV viral load‡ 1.4 0.27 0.062 1.01 - 2.13
EFV concentration‡ 0.4 0.12 0.002* 0.22 - 0.72*
Remove maternal age, BMI, gestational age, count and gravidity as covariates
CD4+ count† 0.9 0.03 0.073 0.99 - 1.00
EFV concentration‡ 1.5 0.12 0.004* 0.23 - 0.71*
HIV viral load‡ 0.4 0.26 0.013* 0.99 - 2.02*
Remove CD4+ count
Plasma EFV concentration‡ 0.6 0.14 0.024* 0.38 - 0.93*
HIV viral load‡ 1.6 0.26 0.005* 1.15 - 2.18*
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age, BMI, duration on cART and gestational age (Suppl. Table 1) was 
observed. Considering the distribution of plasma EFV concentration 
among the participants, with 25% in the subtherapeutic group and 
at risk of viral replication, the 400 mg once-daily dose currently 
recommended partly because of data from the ENCORE1 (efficacy 
of 400 mg efavirenz v. the standard 600 mg dose in HIV-infected 
antiretroviral-naive adults) study, may not be ideal. This study 
concluded that an EFV dose reduction from 600 mg to 400 mg 
once daily would result in optimal therapy.[32] However, considering 
findings from the current study, further reduction of the standard 
dose would further predispose patients in the subtherapeutic group 
to viral replication and risk of developing co-infections. Perhaps, 
genotype-assisted dosing adjustments are ideal. It is worth noting 
that the ENCORE1 study was not carried out in pregnant women, 
and therefore may not be appropriately extrapolated to such women. 
Metabolic aberrations that occur during pregnancy could potentially 
impact drug metabolism. For example, in pregnancy, there is a 
general decrease in albumin content (~30%) in the third trimester, 
resulting in a reduced albumin availability.[33] Albumin binds EFV; 
therefore, increased unbound EFV may increase penetration of 
HIV-infected tissue cells. Furthermore, most of the results from the 
ENCORE1 study are premised on a different population grouping 
compared with participants in our study, who were predominantly of 
African ancestry.[34] 
Understanding factors that influence exposure to drugs is 
important, especially during pregnancy, when there is a risk of 
transmission of antenatal co-infections to the developing fetus. The 
proportion of decreased plasma EFV concentrations and CMV viral 
load in the current study is a cause for concern. It is known that 
subtherapeutic cART concentrations sustain HIV replication. CMV 
and HIV have previously been shown to coactivate each other.[35] The 
current study further supports previous reports, which hypothesise 
that HIV flourishes in patients with low cART concentrations,which 
in turn supports CMV replication, resulting in higher CMV viral 
loads. We also hypothesise the contribution of CMV to poor health 
and hearing impairment experienced by HIV-exposed children 
born to mothers with high HIV viral loads. To further support the 
relationship between HIV replication and the likelihood of CMV 
infection, we found a significant association between increased HIV 
viral load and CMV positivity.
The observed CMV DNA positivity in this study is most likely due 
to CMV reactivation during pregnancy, considering the ubiquitous 
nature of CMV in resource-poor settings. Taylor et al.[36] reported 
that cART acts by disrupting the HIV life cycle, thereby arresting 
viral replication. When there is insufficient cART in circulation, HIV 
replicates, thereby further weakening the immune system. Latent 
viruses such as CMV are reactivated in the setting of compromised 
immunity and chronic immune activation. Hence, subthera peutic 
EFV concentrations predispose to CMV reactivation, which, if 
occurring in pregnancy, may have adverse health outcomes on the 
growing fetus and/or neonate. CMV and HIV have previously been 
found to co-activate each other in vitro and have been described 
as ‘partners in crime’, with CMV viral shedding thereby activating 
the immune system, which then stimulates HIV replication.[13] We 
therefore hypothesise that the subtherapeutic EFV concentrations 
predisposed the pregnant women to CMV infection and perhaps 
reactivation. In view of these findings, dose reduction should only be 
implemented in view of an individual’s genotype to avoid subtherapeutic 
drug concentrations that may predispose to co-infections.
Data in this cohort of pregnant women show that CYP2B6 c.516T 
and CYP2B6 c.983C variants are good correlates of plasma EFV 
concentrations. These findings argue for pharmacogenetic-guided 
EFV dosing. Previous studies have reported similar findings, such 
as a reduced activity of the CYP2B6 enzyme due to the CYP2B6 
c.516G>T and CYP2B6 c.983T>C SNPs.[5,18,26] Consequently, carriers 
of the CYP2B6 c.516T and CYP2B6 c.983C variants have been 
associated with high CYP2B6 substrate drug concentrations, which 
increase with copy number (i.e. CYP2B6 c.516T/T>>>CYP2B6 
c.516G/T>>CYP2B6 c.516G/G, CYP2B6 c.983C/C>>>CYP2B6 
c.983C/T>>CYP2B6 c.983T/T). The CYP2B6 c.516T and CYP2B6 
c.983C alleles both result in reduced enzyme function, leading to 
ineffective metabolism of EFV and high drug concentrations. 
Conclusions
We conclude that subtherapeutic cART concentrations may 
predispose to viral replication and co-infections such as CMV. We 
also confirm that polymorphisms in the CYP2B6 gene are potential 
pharmacokinetic determinants of EFV and as such should be 
considered for dose adjustment. 
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Supplementary Table 1. Stepwise multivariate linear regression of clinical and demographic variables that predict plasma efavirenz 
concentration
Variables Coefficient Standard error p-value 95% CI
CYP2B6 c.516 G/T 0.67 0.13 <0.001* 0.42 - 0.93
CYP2B6 c.516 T/T 1.58 0.15 <0.001* 1.28 - 1.90
CYP2B6 c.983 T/C 0.88 0.17 <0.001* 0.55 - 1.21
Gestational age  –0.01 0.012 0.307 –0.04 - 0.01
Gravidity  –0.01 0.06 0.821 –0.12 - 0.11
Maternal age 0.01 0.013 0.577 –0.02 - 0.032
BMI  –0.004 0.014 0.767 –0.03 - 0.03
CD4+ count†  –0.01 0.01 0.133 –0.001 - 0.0000
HIV viral load  –0.26 0.04 <0.001* –0.35 - 0.18
Remove gravidity and gestational age as covariates
CYP2B6 c.516 G/T 0.68 0.13 <0.001* 0.42 - 0.94
CYP2B6 c.516 T/T 1.59 0.15 <0.001* 1.29 - 1.89
CYP2B6 c.983 T/C 0.91 0.17 <0.001* 0.58 - 1.23
Maternal age 0.01 0.01 0.612 –0.02 - 0.03
BMI –0.01 0.14 0.654 –0.03 - 0.02
CD4+ count† –0.01 0.01 0.128 –0.001 - 0.00001
HIV viral load –0.25 0.04 <0.001* –0.35 - 0.17
Remove BMI, maternal age and CD4+ count
CYP2B6 c.516 G/T 0.68 0.13 <0.001* 0.43 - 0 .94
CYP2B6 c.516 T/T 1.59 0.15 <0.001* 1.30 - 1.90
CYP2B6 c.983 T/C 0.91 0.16 <0.001* 0.60 - 1.23
HIV viral load‡ –0.23 0.04 <0.001* –0.35 - 0.18
CI = confidence interval; BMI = body mass index.
*Statistically significant.
†Square root transformed.
‡Log10 transformed. 
